Main Article Content
Pimecrolimus (SDZ ASM 981), an ascomycin derivative, is a topical nonsteroid calcineurin inhibitor. It exerts anti-intlammatory activity, and has demonstrated efficacy in reducing signs and symptoms of atopic dermatitis in adult and pediatric patients when applied topically. The production of inflammatory cytokines by activated T cells in skin is thought to play an important role in the pathogenesis of atopic dermatitis. Pimecrolimus potently suppresses cytokine production by dermal T cells without significantly impairing systemic immune responses. In randomized controlled clinical studies, twice-daily application of pimecrolimus 1% cream was shown to significantly improve the signs and symptoms of atopic dermatitis in infants, children, and adults. Pimecrolimus is well tolerated. The risk of application-site reactions such as itching or burning is comparable with that of vehicle. Adverse effects were generally mild in patients receiving pimecrolimus 1% cream and occurred at rates comparable with those in patients receiving vehicle treatment. In a 1-year study, pimecrolimus 1% cream significantly reduced the incidence of flares when used at the first signs and symptoms of acute atopic dermatitis. As a result, overall corticosteroid use to treat acute flares was significantly lower in patients using pimecrolimus when the first signs or symptoms of atopic dermatitis appears (early intervention). Furthermore, pimecrolimus 1% cream has shown no potential for skin atrophy, a problem commonly associated with topical corticosteroids treatment. Pimecrolimus provides a promising and well tolerated treatment option in the management of infants, children and adults with mild to moderate atopic dermatitis.
Upon acceptance of an article, the Pharmacological and Therapeutic Society of Thailand will have exclusive right to publish and distribute the article in all forms and media and grant rights to others. Authors have rights to use and share their own published articles.